Loading...
Back to narrative

GLP-1 drugs part of medicare

Update shared on 21 Nov 2025

n/a
n/a
eat_dis_watermelon's Fair Value
n/a
Loading
1Y
26.1%
7D
-5.3%

Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs. No signs of demand slowing down.

Disclaimer

eat_dis_watermelon is an employee of Simply Wall St, but has written this narrative in their capacity as an individual investor. eat_dis_watermelon holds no position in NYSE:LLY. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimate's are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.